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The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to
discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology
and as analytical and therapeutic agents. There was agreement that ncRNA expression proﬁling data
requires careful evaluation to determine the utility of speciﬁc ncRNAs as biomarkers. To advance the use
of ncRNA in regulatory toxicology, the following research priorities were identiﬁed: (1) Conduct
comprehensive literature reviews to identify possibly suitable ncRNAs and areas of toxicology where
ncRNA expression proﬁling could address prevailing scientiﬁc deﬁciencies. (2) Develop consensus on
how to conduct ncRNA expression proﬁling in a toxicological context. (3) Conduct experimental projects,
including, e.g., rat (90-day) oral toxicity studies, to evaluate the toxicological relevance of the expression
proﬁles of selected ncRNAs. Thereby, physiological ncRNA expression proﬁles should be established,
including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for
cell homeostasis or pathogenesis, molecular events should be dose-dependently linked with substance-
induced apical effects. Applying a holistic approach, knowledge on ncRNAs, ‘omics and epigeneticsmond Van Nieuwenhuyse 2
vier Inc. This is an open access article under the Open Government License (OGL) (http://www.nationalarchives.gov.uk/
A. Aigner et al. / Regulatory Toxicology and Pharmacology 82 (2016) 127e139128technologies should be integrated into adverse outcome pathways to improve the understanding of the
functional roles of ncRNAs within a regulatory context.
Crown Copyright © 2016 Published by Elsevier Inc. This is an open access article under the Open
Government License (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/
3/).1. Introduction
1.1. Background
Non-(protein-)coding RNAs (ncRNAs) are broadly classiﬁed ac-
cording to their length as long noncoding RNAs (lncRNAs;
>150e200 nucleotides (nt)) and short ncRNAs (<150e200 nt)
(Wright and Bruford, 2011). Between 4 and 10% of lncRNAs are
further processed to shorter RNAs (Kapranov et al., 2007; Derrien
et al., 2012). Major classes of short ncRNAs include:
1. Endogenous microRNAs (miRNAs; single-stranded, approx.
19e25 nt). MiRNAs are ﬁrst produced as double-stranded RNA
molecules. In this duplex form, they can also be used as thera-
peutic agents. Mature miRNAs are associated with the RNA-
induced silencing complex, where they predominantly repress
gene expression by inducing messenger RNA (mRNA) degrada-
tion or inhibiting mRNA translation (Kim, 2005; Winter et al.,
2009);
2. Endogenous piwi-interacting RNA (piRNA; single-stranded,
approx. 24e31 nt). PiRNAs are believed to be involved in germ
cell formation by post-transcriptional silencing of retro-
transposons and mRNAs in reproductive organs (Watanabe
et al., 2006, 2011; Kuramochi-Miyagawa et al., 2008; Gou
et al., 2014; Williams et al., 2015);
3. Endogenous or synthetically produced short interfering RNAs
(siRNAs; double-stranded, 20e24 nt). Endogenous siRNAs are
also involved in the post-transcriptional silencing of retro-
transposons and mRNAs (Watanabe et al., 2006, 2008). Syn-
thetically produced siRNAs are used as research tools in test
animals (Arrigo and Pulliero, 2015;Wright and Bruford, 2011) or
as therapeutic agents, with several candidates currently being
tested in clinical studies.
Since knowledge on the existence and functionalities of
different forms of ncRNAs is evolving rapidly, this classiﬁcation of
different forms of ncRNA is most likely not deﬁnite. Further classes
of short ncRNAs are known and continue to be discovered, e.g.
small nuclear RNA, small nucleolar RNA, vault RNA, or Y RNA
(Stadler et al., 2009; Martens-Uzunova et al., 2013; Kowalski and
Krude, 2015).
Generally, endogenous ncRNAs have been found to be involved
in post-transcriptional gene silencing, epigenetic regulation and
the mediation of physical and chemical environmental signals.
Although knowledge on how substances can inﬂuence the func-
tionality of ncRNAs is growing, the potential role of ncRNAs in
regulatory toxicology and the risk assessment (RA) of substances
remains to be evaluated.
(Throughout this report, the term ‘substance’ is used as deﬁned
in Regulation (EC) No 1907/2006 on the Registration, Authorisation,
Evaluation and Restriction of Substances (REACH), i.e. a chemical
element and its compounds in the natural state or obtained by any
manufacturing process, including, as applicable, necessary stabi-
lizing additives and impurities deriving from the given production
process.)1.2. Workshop structure and aims
To assess recent progress made on the basic research and use of
ncRNAs as biomarkers in regulatory toxicology and as analytical
and therapeutic agents, the European Centre for Ecotoxicology and
Toxicology of Chemicals (ECETOC) organised the workshop ncRNAs
and risk assessment science. Twenty-two experts representing
academia, authorities, industry, and independent consultants
attended this workshop that took place on 3 and 4 March 2016 in
Malaga, Spain (cf. Appendix for list of participants). As Alan Poole,
Secretary General of ECETOC, Belgium, outlined in the opening, the
workshop aimed at reaching a common understanding on the
state-of-the-art research on ncRNAs, on the implications of ncRNA
expression proﬁle changes for the evolvement of apical effects (i.e.
the observable outcomes of substance exposure to test animals
(OECD, 2012)), and the current and potential future role of ncRNAs
in regulatory toxicology and RA. The ﬁrst day of the workshop
comprised a series of presentations, a panel and extensive plenary
discussions. These sessions focused on understanding the physi-
ology and mechanisms of action of ncRNAs, their functional rele-
vance and possible role in human pathology, and the potential use
of ncRNAs in toxicology and the RA of substances. On the second
day, three breakout groups were formed. In a ﬁrst session, the
breakout groups further discussed means to analyse and interpret
data from ncRNA expression proﬁling for regulatory toxicology and
RA and addressed the question to what extent current regulatory
toxicology would beneﬁt from the evolving knowledge on ncRNA.
In a second session, research priorities were identiﬁed to advance
the use of ncRNAs as biomarkers in regulatory toxicology and RA. In
the long term, all such research should serve the 3Rs principle to
replace, reduce and reﬁne animal testing (Russell and Burch, 1959)
that has been implemented inDirective 2010/63/EU on the protection
of animal used for scientiﬁc purposes. Furthermore, use of ncRNAs in
regulatory toxicology might serve to improve cost efﬁciency and
the timely access to new product developments.2. Presentation summaries
2.1. What are ncRNAs and, speciﬁcally, miRNAs?
Tim Gant, Head of Toxicology, Centre for Radiation, Chemical and
Environmental Hazards, Public Health England (PHE), UK
In searching for ncRNAs as useful biomarkers for regulatory
toxicology, the class of miRNAs may merit special consideration as
their functions in controlling gene expression in a wide variety of
cellular processes (including proliferation, differentiation and
development) as well as their involvement in toxicological and
pathological processes is currently best understood. Further, some
miRNAs exhibit organ-speciﬁc expression, and they can be detected
in the blood plasma. As such, they can act as distant biomarkers of
adverse events. Nevertheless, the potential utility of other forms of
ncRNAs should also be investigated, since they will most likely
assume an equal status as their roles in physiology and disease are
better understood.
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level, i.e. after the given segment of the DNA has been copied into
mRNA. Predominantly, miRNAs degrade mRNAs or they inhibit the
translation of speciﬁc mRNA by binding to their 3'-untranslated
regions (30-UTR), i.e. regions that can inﬂuence the translation ef-
ﬁciency of the mRNAs. Further, miRNAs appear to play a role in the
transgenerational transmission of altered phenotypes through the
male germ line. Compared with mRNAs, only a small number of
miRNAs have been identiﬁed, i.e. 4552 unique human miRNAs (at
the time of writing the workshop report) as compared to 30,000
known human mRNAs. However, one miRNA can regulate the
expression of many mRNAs (by partial complementary base pair-
ing). Hence, even though miRNAs are smaller in number, their ef-
fects on the phenotype of cells can be substantial (Hannon and
Rossi, 2004). On the other hand, different miRNAs can regulate
the same target gene. Therefore, it is necessary to carefully evaluate
the speciﬁc contribution of a given miRNA. By controlling mRNA
translation, miRNAs elicit effects on the cellular protein levels.
Generally, the more miRNA is present in a cell, the less protein will
be translated (Selbach et al., 2008).
MiRNAs can be tissue-speciﬁc, e.g. miR-124 in the brain, miR-
133a in the heart, or miR-122 in the liver, the latter being well
explored in regard to drug overdose-induced hepatotoxicity
(Laterza et al., 2009). Tissue-speciﬁc miRNAs can be relevant bio-
markers for regulatory toxicology, even more so since they are
stable and can be found in all body ﬂuids. Finally, miRNA can play a
role in the evolvement of chromosome aberrations (Calin and
Croce, 2006).
In the human genome, the majority of miRNAs is located in
between genes (i.e. they are intergenic), where miRNAs are
organised into cistronic and polycistronic regions, i.e. regions that
express one or more miRNAs, respectively (He et al., 2005).
Nevertheless, miRNAs are also found in the introns of genes, in
which case they are controlled by a mRNA promoter and enhancer
region. Such miRNAs often act as feedback loops to the genes in
which they are contained. Finally, the smallest group of miRNAs are
exonic (Gant et al., 2015). During embryonic development, miRNAs
can be involved in the very early stages of gene transcription that
begins in zygotes during the eight-cell stage. It is hypothesized that,
if such gene transcription processes are disturbed, e.g. by envi-
ronmental or epigenetic factors, the phenotype of the resulting
embryo can potentially be affected (Trerotola et al., 2015).
2.2. Mechanisms of action of ncRNAs and functional relevance
Gunter Meister, Biochemistry Centre Regensburg, Regensburg
University, Germany
Small ncRNAs are found in all higher eukaryotes. They play key
regulatory roles in cellular processes that are as diverse as em-
bryonic development, stress response and transposon silencing. All
small ncRNA species are generated from longer precursor mole-
cules and are ﬁnally incorporated into effector protein complexes.
Of the small ncRNAs, recent research has focused on miRNAs that
guide post-transcriptional, temporary gene silencing. This is
mediated by members of the so-called argonaute (AGO) protein
family that bind to the miRNAs (Huntzinger and Izaurralde, 2011;
Meister, 2013; Schraivogel and Meister, 2014; Dueck and Meister,
2014; Jonas and Izaurralde, 2015).
Second, lncRNAs are being extensively studied. In mammals,
lncRNAsare found in thenucleusand in the cytoplasm. In thenucleus,
they mainly associate with chromatin and regulate the expression of
speciﬁc genes. In the cytoplasm, they can bind tomRNAs thereby also
inﬂuencing post-transcriptional gene expression. LncRNAs can func-
tionasguides (enhancersofproper localizationofproteincomplexes),
sponges (by binding to complementary RNAs which inhibits theirfunctionality), scaffolds (adaptors to bring two or more proteins into
discrete complexes) or even nucleators for higher order chromatin
structures (Ebert and Sharp, 2010; Salmena et al., 2011; Rinn and
Chang, 2012). Similar to small ncRNAs, lncRNA expression is
frequently altered in human diseases.
Recently, circular RNAs have been characterized (Hentze and
Preiss, 2013). Circular RNAs can be abundant under speciﬁc con-
ditions or in speciﬁc tissues (e.g. the brain); they are generated by
alternative splicing, and they can act as sponges for RNAs and
proteins. Apparently, some circular RNAs even have coding poten-
tial and can contribute to the diversiﬁcation of gene products.
Finally, epitranscriptome, i.e. sugar or base modiﬁcations that
are introduced into mRNAs (i.e. the transcriptome) after synthesis,
constitute procedures that, similar to epigenetics, exist 'on top' of
the synthesis of coding and non-coding transcripts. For many years,
it has been known that ribosomal and transfer RNAs can be
modiﬁed at particular bases. Recently, it was found that mRNAs can
also be modiﬁed and that this can inﬂuence gene expression. RNA-
binding proteins can associate with transcripts, thereby changing
their function independently of their sequence. Further, RNAs were
found to cross-talk by hybridisation, i.e. pairing to complementary
RNA (Lin and Gregory, 2014). All of these factors should be taken
into account when analysing gene expression. Most likely, to date,
only the ‘tip of the iceberg’ has been uncovered, and many more
such modiﬁcations with important biological functions remain to
be detected.
2.3. Expression of macroscopic phenotypes for miRNA-guided
regulation at the molecular level
Herve Seitz, Institut de Genetique Humain (IGH), Centre National
de la Recherche Scientiﬁque (CNRS), Montpellier, France
MiRNAs can play regulatory roles by pairing to the mRNAs of
protein-coding genes to direct their post-transcriptional repression
(Bartel, 2009). According to the current view, each miRNA regulates
hundreds of genes (Lam et al., 2015). Computational tools aim at
identifying miRNA targets, looking for seed-matches (i.e. comple-
mentary sequences) in the 30 UTRs of miRNAs and mRNAs (Bartel,
2009). Usually, this is performed by selecting evolutionarily
conserved miRNA binding sites. However, frequently, such pre-
dictions are biologically irrelevant, since short matches are very
frequent. Sixty per cent of human coding genes seem to be targeted
(Friedman et al., 2009), and miRNAs are implicated in every phys-
iological process in animals. Nevertheless, miRNA-mediated gene
repression is usually very modest, i.e. less than two-fold, which is
lower thanwell-tolerated ﬂuctuations in gene expression. Focusing
on miR-223-guided gene repression, Baek et al. (2008) measured
miRNA-guided repression in vivo. Work conducted in the pre-
senter's laboratory shows that inter-individual variability in wild-
type mice is larger than miR-223-guided repression for 150 out of
192 predicted targets. Hence, most predicted targets appear func-
tionally insensitive to the miRNAs. Moreover, many conserved
miRNA binding sites appear to be conserved in a miRNA-
independent fashion. It is unclear, why miRNA binding sites have
been conserved since they do not appear to be functional. Sequence
elements can be conserved for other reasons, while being fortu-
itously complementary to miRNAs. Accordingly, comparative ge-
nomics can yield a high proportion of false positive results.
In revisiting the deﬁnition of a ‘miRNA target’ it is concluded
that not every measurable change in gene expression translates
into a macroscopic, evolutionarily selectable phenotype. The role of
miRNAs in normal and pathological conditions might have been
over-estimated, and the very notion of ‘gene regulation’ should be
reconsidered taking into account the robustness of cellular ho-
meostasis to external insults. It appears difﬁcult to reconcile such
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tuning. Most likely, the 'butterﬂy effect' (indicating that a small
dose can trigger a substantial consequence, i.e. phenotypic alter-
ation) has been counter-selected for.
2.4. Cellular adaptation: relevance for risk assessment and
physiological interpretation
Emma Marczylo, PHE, UK
The vast majority of the mammalian genome is composed of so-
called noncoding DNA, whereas only approx. 1e2% of the
mammalian genome code for proteins. The majority of noncoding
DNA is transcribed into ncRNAs, which play major roles in regu-
lating gene expression. Whilst lncRNAs do this in a variety of ways,
including chromosome remodelling and transcriptional or post-
transcriptional regulation, short ncRNAs predominantly regulate
gene expression at the post-transcriptional level. NcRNAs interact
with epigenetic mechanisms to form a robust regulatory epigenetic
network (Marczylo et al., 2016). Many ncRNAs, particularlymiRNAs,
have been shown to be involved in both toxicity and disease. Spe-
ciﬁcally, ncRNA play a central role during cellular adaptation in
response to changes in the environment. Following exposure to an
environmental stressor, cellular processes are activated in an
attempt to regain homeostasis. These processes can be transient,
returning to the original state once the insult is removed, or they
can become established as the ‘new homeostasis’. Such adaptations
can be positive, providing protection against further stress
(Wheeler and Wong, 2007; Jain et al., 2014); or they can be nega-
tive, resulting in an increased susceptibility to further stress
(Greathouse et al., 2012; Wong et al., 2015). If cells are unable to
adapt to an environmental stressor, adverse effects can evolve that
can either be reversible (leading back to homeostasis) or irrevers-
ible which ultimately results in cell death. For RA, it is important to
distinguish between cellular adaptation and adverse effects.
In determining cellular ‘normality’ with the aim ofmaking use of
ncRNAs for RA, it is important to understand and characterise the
variability in ncRNAs (both within individuals (tissue speciﬁcity)
and between different individuals and different species) that are
present in the same steady state (normal environment). For
instance, more than 500 different miRNAs were present in the
plasma of 18 disease-free human volunteers. Of these, approx. 50
miRNAs were present in all samples. Further, 10 of the most highly
expressedmiRNAs accounted for 90% of the totalmiRNA expression,
and 5 of these were blood cell-associated. Finally, 10 of the most
stably expressed miRNAs included 5 of the most highly expressed
(Tonge and Gant, 2016). Variability in ncRNA expression should also
be understood in response to changes in the normal environment
that do not exert adverse effects both within individuals and be-
tween individuals. This will enable identiﬁcation of genetic sus-
ceptibilities, normal ranges of ncRNA expression, and adaptations
with increased susceptibilities to further stresses/exposures.
In determining the relevance of miRNA-initiated cellular adap-
tations to environmental stressors, it is important to distinguish
whether the change in ncRNA expression is the cause or the
consequence of an apical effect. Yet, whilst a robust, dose-
dependent relationship between speciﬁc ncRNA(s) and environ-
mental stressor(s) or subsequent effect(s) is vital for RA, estab-
lishing causality is not necessarily essential. NcRNAs that do not in
themselves directly induce adverse effect(s), but instead act as
markers of exposure and/or predictors of future toxicity, can also be
useful in regulation (Marczylo et al., 2016). Increasingly, the po-
tential use of miRNAs as biomarkers is being investigated since they
are secreted in multiple body ﬂuids (including blood, semen,
saliva), and they are stable (secreted within exosomes), accessible,
and easily measured (Gant et al., 2015). Spermatozoal miRNAs areof particular interest for regulatory purposes since they can be
altered by environmental exposures, transmitted across genera-
tions, involved in the physiological or pathophysiological devel-
opment of subsequent progeny and are easily collected and
analysed (Liu et al., 2012; Marczylo et al., 2012; Rodgers et al., 2013,
2015; Gapp et al., 2014; Stowe et al., 2014). To be used as bio-
markers, ncRNAs should further be sensitive, speciﬁc, and linearly
related to exposure and effect.
With regard to the physiological interpretation (i.e. phenotypic
anchoring) of alterations in ncRNA expression, these molecules
pose unique challenges since they act at multiple levels forming
part of an interactive network. For example, miRNAs have multiple
mRNA targets, just as potential mRNA targets are targeted by
multiple miRNAs. Consequently, the interpretation of observations
can be challenging. To facilitate phenotypic anchoring, ncRNA
expression proﬁles can be correlated with other proﬁles and
phenotypic endpoints (Akinjo et al., 2016). In this respect, ‘omics
technologies allow simultaneous proﬁling of multiple variables
using a systems biology approach.
In conclusion, ncRNAs are important regulators of gene
expression and represent novel mechanisms and markers of
toxicity that might be useful for regulatory purposes. To explore
such use, a greater mechanistic understanding should be obtained,
e.g., by performing additional analyses on surplus biological sam-
ples from existing regulatory studies, thereby avoiding the use of
extra animals. It might also be considered to adapt existing testing
guidelines to incorporate ncRNA analyses, as appropriate, to begin
collecting data on ncRNA in a regulatory context.
2.5. Cross-kingdom RNA effects and modes of ncRNA exposure
Kenneth W. Witwer, Johns Hopkins University School of Medicine,
USA
In cross-kingdom RNA communication, the nematode Caeno-
rhabditis elegans is the known champion, using ingested environ-
mental RNA as a type of immune system (Jose, 2015). Such cross-
kingdom communication has also been described or proposed in
various host-pathogen interactions, e.g., in the relationship of ret-
roviruses with their hosts (Klase et al., 2007; Wagschal et al., 2012;
van Dongen et al., 2016). Applied tomammals, the so-called ‘dietary
RNA hypothesis’ suggests that intact RNAs present in the food
might enter the ingesting organism and exert gene expressional
functions in its cells (Witwer and Hirschi, 2014). Studies of
mammalian uptake have focused mostly on miRNAs, or ‘xenomiRs’
to denote their foreign origin. However, in the meantime, enthu-
siasm about the absorption and function of xenomiRs has been
diminished by negative ﬁndings and evidence of contamination
and experimental design ﬂaws that account for apparently positive
results (Mlotshwa et al., 2015). Nevertheless, despite scant and
suspect evidence for the hypothesis, interest is likely to continue
into the foreseeable future. Focusing on mammals exposed to
plants and milk (Dickinson et al., 2013; Snow et al., 2013; Witwer
et al., 2013; Baier et al., 2014; Tosar et al., 2015), experimental re-
sults and current understanding of RNA stability, transport, and
function do not appear to be consistent with proposed forms of
cross-kingdom communication. In many cases, presumably posi-
tive ncRNA ﬁndings were shown to result from, e.g., sample con-
taminations or artefacts caused by technical limitations of the
applied technologies (Witwer, 2015).
2.6. Links between changes in ncRNA expression and phenotypic
alterations
J€org Hackermüller, Young Investigators Group Bioinformatics and
Transcriptomics, Department of Molecular Systems Biology, Helmholtz
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Considering that mammalian cells are capable of producing a
plethora of ncRNAs, the question arises to which extent non-coding
transcription is functionally important. Are changes in ncRNA
expression causal for diseased or adverse states or a consequence
thereof? Even if the latter is the case, ncRNAs might still form a
valuable pool for biomarkers of adversity or disease. However, if
ncRNAs play in part causal roles, do we need to consider ncRNAs in
mode-of-action (MoA) frameworks or adverse outcome pathways
(AOPs; Ankley et al., 2010)? If so, is it already possible to deﬁne
MoAs or AOPs where ncRNAs participate in key events?
The example of interleukin 6 (IL-6) and signal transducer and
activator of transcription 3 (STAT3)-controlled ncRNAs served to
further elucidate these questions. Speciﬁc multiple myeloma (B cell
malignancy) cells depend strictly on IL-6 and become apoptotic
when IL-6 is not present. However, this cellular phenotype cannot
be explained by an IL-6-enabled differential expression of protein-
coding genes (Brocke-Heidrich et al., 2004). Instead, the miRNA
miR-21 appears responsible for the anti-apoptotic effect of IL-6 and
indeed shows strong differential expression in B cell malignancy
cells (L€ofﬂer et al., 2007). Further, miR-21 has been observed to
target the tumour suppressor genes ANP32A, PDCD4 and SMARCA4
(Schramedei et al., 2011). IL-6 and STAT3 have been observed to
control a plethora of lncRNAs and to regulate a set of macroRNAs
(including STAiRs; STAT3-induced RNAs) that are in part speciﬁc for
multiple myeloma (Hackermüller et al., 2014). Some STAiRs seem to
be tightly coupled with IL-6 signalling via STAT3 and inherent
components of this pathway.
Even though knowledge on such speciﬁc interactions is begin-
ning to evolve, for several reasons, it can be difﬁcult to ascertain the
causality of the expression of a given ncRNA: The speciﬁc effects
that a ncRNA can exert on the regulation of gene expression can
depend on a given context. With the exception of some classes of
small ncRNAs, limited conservation at the primary sequence level
complicates tracing ncRNAs between model animals. Finally,
ncRNAs have been found to interfere with pathways at multiple
levels. This may have pronounced consequences for the entire
pathway, even though individual interactions only elicit small ef-
fects (e.g., Boll et al., 2013). Nevertheless, increasingly, the role of
lncRNAs in toxicity testing is being addressed, such as the effects of
chemicals on lncRNA H19 and other imprinted genes as well as the
lncRNA Hox gene transcript antisense RNA (HOTAIR; Croce, 2010;
Bhan et al., 2014). Taken together, these ﬁndings may form the
basis for an AOP. Non-coding loci are also of increasing interest in
environmental epidemiology. Deep methylome sequencing (i.e. an
analysis of the methylation status of the genome) in a mother-child
cohort study identiﬁed numerous differentially methylated regions
of the DNA (DMRs) in children that were affected by their mothers’
smoking habits. The majority of DMRs was associated with non-
coding targets, and differential methylation was in part found to
persist over years (Bauer et al., 2016).
In conclusion, to a larger part, the differential expression of
ncRNAs may be a consequence of disease or adverse effect, but
many short ncRNAs do play a causal role in disease. Also for a
growing number of lncRNAs, either mutation or changes in
expression have been found causal for disease. Even though, to
date, only few lncRNAs have been associated with pathways of
toxicity, and knowledge on their role in the evolvement of apical
effects is still limited, lncRNAs, and not only miRNAs, should be
considered in AOP or MoA analyses.
2.7. Substance-induced alterations in ncRNA expression proﬁles
Nigel Gooderham, Computational and Systems Medicine, Depart-
ment of Surgery and Cancer, Imperial College London, UKMiRNAs are an abundant class of genes in mammals that may
control gene expression through translational repression and by
inducing mRNA degradation. Since miRNAs regulate development,
cell proliferation, apoptosis and differentiation, they play a central
role in processes that are potentially important in toxicology.
Speciﬁcally, miRNAs have been shown to interact with cellular
pathways that are relevant for carcinogenesis (Calin and Croce,
2006). Tumour-suppressor miRNAs may negatively regulate pro-
tein coding oncogenes, whereas oncogenic miRNAs may repress
tumour suppressor genes. MiRNAs may also alter the epigenomics
landscape by reprogramming a cell's epigenome (Moazed, 2009).
For instance, miR-29 has been observed to inhibit the expression of
DNA (cytosine-5-)-methyltransferase 3 (Fabbri et al., 2007), and
miR-101 regulates the histone methyltransferase EZH2 (enhancer
of zester homolog-2) (Floris et al., 2015). Further, combinations of
miRNA may cooperate to regulate multiple proteins within cancer-
important pathways.
Currently, genotoxic carcinogens can be identiﬁed reliably and
quickly using a weight-of-evidence approach that takes into ac-
count structural information, in vitro assays, and in vivo DNA
damage assays. By contrast, there are no regulatorily-accepted
short-term tests that allow predicting non-genotoxic carcinoge-
nicity. To investigate if changes in miRNA expression might
constitute early indicators of substance-induced carcinogenicity
with adequate sensitivity and speciﬁcity, and provide information
on mechanisms of toxicity, a spectrum of liver carcinogens was
investigated in 90-day oral toxicity studies in Fisher rats. Between 3
and 5 animals per treatment group were used. The liver carcino-
gens were applied at carcinogenic doses, whereas additional non-
carcinogenic substances were applied at the respective maximum
tolerated dose. In none of the test groups did tumours become
evident by the end of the exposure period.
Total RNA was extracted from the liver and ﬂuorescently
labelled. RNA quality was determined using an Agilent Bioanalyser,
and expression proﬁles were assessed using the Agilent miRNA
microarray platform and microarray scanner. The scan data were
further processed using the Agilent Feature Extraction software. For
miRNA hybridisation signals (i.e. for the detection of expressed
miRNA), a threshold of 1 was set, the signals were log-2 trans-
formed, and miRNA expression was normalised to the 75th
percentile using the GeneSpring GX software (all equipment and
software: Agilent Technologies, USA). One-way ANOVA with
Benjamini-Hochberg multiple testing correction followed by
Tukey's test was used to identify dysregulated miRNAs. Targeted
quantitative real-time polymerase chain reaction (qRT-PCR) was
used to conﬁrm differential miRNA expression between control and
test groups.
MiRNAs that were not detected in at least 50% of the samples of
any test group were excluded from the evaluation. Thereby, 21
miRNAswere identiﬁed as differentially expressed, and hierarchical
clustering revealed speciﬁc patterns of miRNA expression (Koufaris
et al., 2012). These miRNAs appeared to regulate pathways that are
frequently disrupted during chemical carcinogenesis or implicated
in the progression or suppression of carcinogenesis, and these same
miRNAs had previously been found to be dysregulated in tissue-
speciﬁc tumours. Bioinformatic analysis indicated that speciﬁc
pathways (such as phosphoinositide 3-kinase or epidermal growth
factor) were targeted and over-represented in the analysis. This
points to the need to assess the biological plausibility of the pre-
dicted miRNA-regulated pathways in respect to cancer
development.
Further, a 14-day rat oral toxicity study was conducted to
investigate whether the tumour promoter phenobarbital elicits
miRNA-related effects in a temporal and dose-dependent manner.
Again, total RNA was extracted from the liver, labelled and proﬁled
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nologies, USA). While there were no obvious statistically signiﬁcant
microarray responses during the ﬁrst 7 days of treatment, within 14
days, clustering could be observed and a distinct dose-related time-
dependent effect on the miRNA expression proﬁles could be shown
(Koufaris et al., 2013).
In summary, the mentioned 90-day and 14-day studies suggest
that both genotoxic and epigenetic carcinogens can dysregulate
miRNA expression to produce a ‘ﬁngerprint’ that can be detected
long before tumours develop in the treated animals. The miRNA
‘ﬁngerprint’ appears to be compound-speciﬁc, and it appears to
change in a dose- and time-dependent manner. Details of the
miRNA ‘ﬁngerprint’ can offer insight into potential MoAs. Conse-
quently, the concept that miRNAs are biomarkers of toxicity, such as
substance-induced carcinogenesis, is highly attractive. It offers the
potential to identify translational biomarkers that reﬂect the pro-
gression of such pathological conditions (Koufaris and Gooderham,
2013; Gooderham and Koufaris, 2014).
2.8. NcRNA therapy: upcoming medical applications
Achim Aigner, Rudolf-Boehm-Institute for Pharmacology and
Toxicology, Clinical Pharmacology, Leipzig University, Germany
In the past years, increasing insight has been gained into the
physiological and pathophysiological roles of many important
classes of ncRNAs. This also included the discovery of new gene
silencing mechanisms, such as RNA interference (RNAi) or miRNA-
mediated inhibition of speciﬁc protein synthesis. These discoveries
have substantially enhanced the understanding of intra- and
extracellular communication beyond proteins, and they provide
important information on the basis of various diseases involving
aberrant ncRNA expression. Importantly, they also allow for the
exploration of these mechanisms for therapeutic purposes. Major
players of RNA-based therapies include antisense oligonucleotides
and siRNAs, locked nucleic acid anti-miRs, tiny locked nucleic acid
anti-miRs, miRNA sponges and antagomiRs (i.e. chemically modi-
ﬁed oligonucleotides that target speciﬁc miRNAs), miRNA mimics
and ribozymes.
As a rule, RNA-based therapeutic agents are too large as mole-
cules, negatively charged and not sufﬁciently stable in biological
ﬂuids. This constitutes technical disadvantages over many other
pharmaceuticals mainly with regard to poor pharmacokinetics.
Therefore, chemical modiﬁcations and/or formulations have to be
implemented to allow for therapeutic use, and despite many years
of research, the issue of delivery still remains a major obstacle in
therapeutic RNA use. While problems persist, RNA-based thera-
peutics allow for broader target selection and offer new therapeutic
strategies particularly as they do not in general elicit antibody re-
sponses, even when they are bound to proteins (Ling et al., 2013).
NcRNA-based therapies either aim at restoring normal ncRNA
functionalities or at using small RNA molecules to trigger desired
therapeutic effects. For example, RNAi allows for the inhibition of
any target gene of choice. This provides the opportunity to develop
novel concepts in therapy also with regard to otherwise ‘undrug-
gable’ genes.
Consequently, since its discovery in the late 1990s, RNAi-based
therapeutics have been used in more than 50 clinical trials
involving 26 different siRNAs (Ling et al., 2013; Lundin et al., 2015;
Wittrup et al., 2015). Two phase III clinical trials are in progress to
treat familial neurodegenerative and cardiac syndromes caused by
transthyretinmutations (Singh and Peer, 2016) while studies on the
potential of miRNA replacements or miRNA inhibitions to reduce
hypertrophic dermal scarring by targeting connective tissue
growth factor or to treat pancreatic cancer have also started (Singh
and Peer, 2016). Outstanding issues in ncRNA therapy, however, aretargeted RNA-drug delivery to speciﬁc organs, speciﬁcity, efﬁcacy
and absence of side effects (Wittrup et al., 2015). Various RNA-
delivery strategies, including the use of nanocarriers, and chemi-
cal RNA modiﬁcations have been developed and are currently un-
der pre-clinical and clinical investigation (Dai and Tan, 2015;
Grünweller and Hartmann, 2016; Singh and Peer, 2016).
2.9. Technical issues related to the use of ncRNAs as biomarkers for
regulatory toxicology
Frank Slack, Department of Pathology, Director, Institute for RNA
Medicine, Beth Israel Deaconess Medical Center - BIDMC Cancer
Center Harvard Medical School, USA
MiRNAs have been found in all multicellular eukaryotes inves-
tigated so far, and they can regulate the expression of important
disease genes, e.g. oncogenes and tumour suppressors (Chen et al.,
2008; Chin and Slack, 2008; Lawrie et al., 2008; Mitchell et al.,
2008). Accordingly, miRNAs can be useful diagnostic and prog-
nostic markers for diseases, and they are emerging as therapeutic
targets and targeted therapeutics in different diseases, including
cancer (Lu et al., 2005; Calin and Croce, 2006; Kasinski and Slack,
2011). For instance, RNA expression proﬁling points to miR-34a as
important and prognostic biomarker in triple-negative breast
cancer (Kato et al., 2009; Adams et al., 2016).
A suitable starting point in investigating the applicability of
miRNAs as therapeutic targets or agents is to measure their relative
or absolute levels in normal and diseased tissues. MiRNA proﬁles
can be obtained from (fresh, ﬁxed or frozen) tissues, organs, cells
and subcellular fractions as well as from all relevant body ﬂuids.
MiRNAs are stable in the blood and other body ﬂuids (Weber et al.,
2010; Mitchell et al., 2008).
Technologies for detecting miRNAs include Northern blotting, in
situ hybridisation, (low density) qRT-PCR, microarray technologies,
and miRNA sequencing (RNA-Seq) (Johnson et al., 2007; Chiang,
2014). Each technology has its own strengths and limitations.
While Northern blotting has very low throughput and sensitivity, it
can often detect both mature and precursor forms of miRNA. In situ
hybridisation also has low throughput and low sensitivity, but it
provides the opportunity to detect the localization of miRNAs in
tissues and subcellular regions. Microarray technologies are rela-
tively cheap, but they have lower speciﬁcity and dynamic ranges
than other technologies since the microarray platforms can only
detect the speciﬁc RNAs for which they were designed. QRT-PCR
has high sensitivity and speciﬁcity, and low and medium
throughput options are commercially available. While RNA-Seq is
relatively expensive, it has an extremely high throughput, it is
highly sensitive, and it provides the option of detecting novel
miRNAs and other RNA species (Baker, 2010).
Even though miRNAs rankings are concordant between
different technologies, their outcomes cannot be compared in a
quantitative manner (Baker, 2010). One of the drawbacks of RNA-
Seq is that many miRNAs have isomeric forms that can be detec-
ted using RNA-Seq, but possibly not with other detection systems.
As a result, it is difﬁcult to directly compare the data obtained using
different technologies. Further challenges to the detection and
diagnostic use of miRNAs include the small sizes of the molecules,
delivery and speciﬁcity issues, the determination of ‘normal’
miRNA levels, and the fact that very many miRNAs are only
expressed at very low levels (Cheng et al., 2015). Even though the
available technologies allow detecting such low levels of miRNAs,
their biological implications remain to be determined.
Generally, whereas miRNA expression proﬁling provides ﬁrst
information on biomarkers of interest, miRNA levels alone do not
allow determining their functionalities (Pritchard et al., 2012). As a
rule, such determinations require mouse knock-out or knock-in
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inhibit miRNA function and/or expression, miRNA mimics that in-
crease miRNA expression, viral pre-miR and miRNA sponges or
miRNA luciferase sensors.
2.10. Risk assessment considerations for ncRNAs in agricultural
products and applications
Jan Verhaert and Jay S. Petrick, Monsanto Company, Belgium and
USA, respectively
The RNA interference (RNAi) pathway has been recognized in
crops for over a decade. Recent advances in technology have lead to
advances in agricultural applications based on the RNAi pathway.
RNA-based traits are the basis for phenotypes in conventional
crops, with soybean seed coat colour andmaize stalk colour serving
as examples of RNA-based gene regulation harnessed through se-
lective breeding (Tuteja et al., 2004; Della Vedova et al., 2005;
Koseki et al., 2005). In addition, RNA-based technologies have
been successfully employed to introduce new traits in crops, such
as virus resistance, altered oil composition in soybeans, and insect
protection against corn rootworm. These types of traits have been
risk assessed and approved by multiple regulators across the globe.
RNA has an extensive history of safe consumption, and humans and
animals routinely consume small RNAs and longer double-stranded
RNAs in staple foods that have 100% sequence identity to the
consuming human or animal without impact to health (Ivashuta
et al., 2009; Jensen et al., 2013; Frizzi et al., 2014). This safe con-
sumption results in part from extensive barriers to ingested RNAs,
such as low gut pH, nucleases, multiple membrane barriers, and
rapid renal elimination of RNA (Petrick et al., 2013). These barriers
are also evidenced by drug delivery challenges faced by developers
of oligonucleotide-based drugs (Juliano et al., 2009; O'Neill et al.,
2011; Petrick et al., 2013). Further studies in mammals indicate
that ingested double-stranded RNAs, even those targeting a gene in
the test species, do not produce adverse health effects in these
animals (Petrick et al., 2015). Whereas RNA-based technologies
provide new tools to address agricultural challenges, the overall
weight-of-evidence including historical knowledge as well as new
empirical evidence shows that these technologies are safe and their
safety assessment can be addressed using the current safety
assessment framework.
3. Panel discussion: enhancing the applicability of ncRNAs as
biomarkers for risk assessment
The moderator of the panel discussion, Saskia van der Vies, VU
University Medical Centre, NL, invited all panellists (see below) to
make a statement addressing the following questions: How is the
abundance of ncRNAs currently managed? Which knowledge gaps
and knowledge needs prevail that stand in the way to applying
ncRNAs as biomarkers for regulatory toxicology and RA? Which
ncRNA-related data are relevant for RA? What is key to data anal-
ysis and data evaluation? The statements from the panellists were
followed by an open ﬂoor discussion.
3.1. Statements from the panel
Frank Slack, Harvard University, USA: It is equally evident that
ncRNAs have great potential to be used as biomarkers and that
extensive knowledge gaps must be addressed before this goal can
bemet. Current investigations focus on analysing data to determine
the best suitable ncRNAs and to elucidate how they ﬁt into speciﬁc
pathways. Generally, knowledge on ncRNAs is just beginning to
evolve, and new classes of RNAs, such as circular RNAs, have only
been discovered in the last years. Therefore, also an understandingon their tissue-speciﬁc presence or functionalities is still at its very
beginning. It is very likely that further classes of RNAs remain to be
discovered, just as miRNAs might not be the smallest RNAs present
in organisms.
Reza J. Rasoulpour, Dow AgroSciences, USA: The available
knowledge on ncRNAs can indirectly or directly beneﬁt substance
RA, i.e. when new molecules are concertedly designed, on the one
hand, and when speciﬁc ncRNA signatures are identiﬁed in test
animals, on the other hand. In combining exposure and hazard
assessment during RA, ncRNA expression proﬁling can provide
biological explanations on the mechanisms of toxicity that spe-
ciﬁc substances can affect. Eventually, such ncRNA expression
proﬁling might provide opportunities to improve regulatory
toxicity testing.
Kerstin Schmidt, BioMath GmbH, Germany: The time- and dose-
dependent up- and down-regulation in response to toxic sub-
stances qualiﬁes ncRNAs as useful biomarkers for toxicological
studies. NcRNA expression proﬁles might supplement or even
substitute conventional parameters that are obtained by, e.g.,
haematology or clinical biochemistry. NcRNAs, as new parame-
ters, could be integrated into consolidated test vs. control group
comparisons. Basically, the familiar principles to statistically
analyse potential apical effects and dose-response relationships
are also adoptable to ncRNA expression proﬁling. In fact, such
approaches are very similar to current toxicological testing: Even
though only single parameters are measured in the current
toxicity tests, these parameters are jointly evaluated to address
complex toxicological endpoints. Challenges of quantiﬁcation and
data interpretation are not limited to the harmonization of tech-
niques to measure ncRNAs. Standardized procedures are also
needed for data normalization and referencing. Further, standard
statistical estimators must be established to ensure comparability
and to facilitate assessment, also of the biological relevance of
effects. Historical control data and effect sizes of potential toxi-
cological interest (e.g. with respect to the up- or down-regulation
of genes) have to be established. It has to be clariﬁed whether the
test group sizes indicated in current test guidelines provide suf-
ﬁcient statistical power to detect ncRNA effect sizes. Finally,
modern statistical methodologies and presentation methods
should be implemented to enhance comprehensive analyses and
interpretation of results (Schmidt et al., 2016).
Tim Gant, PHE, UK: Research on ncRNAs is a technology-driven
process that yields an abundance of data. In making use of ncRNA
expression proﬁles for RA, interpretation of the collected data is the
biggest challenge, as is also known for ‘omics technologies. Some of
the information that these technologies provide is not necessarily
fully understood. Nevertheless, it is beneﬁcial to gather all data,
even though it can be challenging to manage large datasets.
Knowledge gaps with respect to evaluating data by applied bioin-
formatics prevail. It is not yet understood which speciﬁc data are
relevant for toxicological RA, which changes in ncRNA expression
are causal and which are consequential, or how ncRNAs are
involved in toxicological mechanisms. Such an understanding,
however, is a prerequisite to selecting ncRNAs as biomarkers for RA.
Presumably, different types of substances and different patterns of
change are related to speciﬁc mechanisms of toxicity.
3.2. Open ﬂoor discussion
Generally, cells can counterbalance external insults with sufﬁ-
cient efﬁciency until a certain level or duration of exposure. Alter-
ations in ncRNA expression proﬁles can indicate a cell's attempt to
regain homeostasis, and, therefore, they can be recorded before the
cell is irreversibly damaged. As such, changes in ncRNA expression
can constitute molecular initiating events. However, depending on
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an AOP. In both cases, relevant ncRNAs can be early predictors of
speciﬁc toxicological pathways. Hence, they can become useful
biomarkers for regulatory toxicology. To understand mechanisms
of toxicity, the point at which the system is irreversibly disrupted
should be identiﬁed. Further, to build a mechanistic understanding
on ncRNA-induced effects, it is essential to establish dose-response
relationships of alterations in ncRNA expression proﬁles. Another
key issue is to determine if changes are sensitive. Very often,
changes are small (e.g. ﬁve-fold increases of singular molecules), in
which case they are difﬁcult to detect.
Extensive discussions addressed the question whether ncRNA
expression changes were ‘cause or consequence’ of adverse effects
and what implications this might have in making use of ncRNA
technologies in regulatory toxicology. While ncRNA expression
changes might not be directly causative, the subsequent down-
stream effects might nevertheless induce toxicity. Such ncRNA
expression changes can be thought of as causal. By comparison,
ncRNA expression changes that occur in response to a particular
exposure and/or toxicity, but that are not involved in the induction
of adverse downstream effects, can be thought of as consequential.
Such changes may also be useful as biomarkers of substance
exposure in regulatory toxicology. Even if it is not fully understood
whether alterations in the expression of a given ncRNA are ‘cause or
consequence’ of a speciﬁc apical effect, this ncRNA may neverthe-
less be a potentially useful biomarker for regulatory toxicology and
RA.
From a toxicological point of view, concerns regarding the
applicability of ncRNA expression proﬁling are similar to the ones
that have been voiced with respect to gene expression (tran-
scriptome) proﬁling. Data can indicate that, e.g., speciﬁc carcino-
genic genes are enhanced or expressed. Upon too simplistic
evaluation, this can be interpreted as giving rise to concern, even in
the absence of a downstream apical effect. It is essential to un-
derstand the phenotypic consequences of a given ncRNA change,
i.e. to perform a functional veriﬁcation and validation of the ncRNA
expression proﬁle. At best, the physiological and pathological roles
of all ncRNAs that rank high in expression proﬁles should be
known. To date, such functionalities are investigated rather
randomly by changing the expression of a speciﬁc ncRNA, e.g. by
using knockout animals (or genetically modiﬁed cell lines) that lack
a speciﬁc gene or ncRNA and searching for phenotypic (or cellular)
alterations.
A way forward in identifying ncRNA ﬁngerprints that might be
applicable to determine, e.g. a substance's carcinogenic potential,
might be to expose different animal species to a set of substances
with known carcinogenicity and to comparatively assess the
resulting ncRNA expression proﬁles. Generally, the most relevant
animal species and animal model for a given human issue should
be identiﬁed, just as the human health relevance of ﬁndings
should be ensured. Research should also aim at investigating the
biological implications of (different levels of) ncRNAs present in
body ﬂuids. Even though ncRNAs (just as other biomarkers in the
blood) can be exceptionally stable when bound to proteins, they
can nevertheless be removed from the blood very quickly, i.e.
before sampling can be performed. To date, it is largely unclear
from which organs or tissues the ncRNAs present in body ﬂuids
come from, or if they are truly speciﬁc to the process under
investigation.
Importantly, research reports should not only include all data
that were collected, but they should also clearly describe how the
data were collected and analysed. Further investigations should
aim at identifying the technology that is best suited to determine
biologically relevant ncRNA alterations (that are not merely tech-
nological artefacts or sample contaminations).4. Breakout sessions: the identiﬁcation of research priorities
Therewas considerable overlap between the topics addressed in
the breakout groups with resulting concordant or complementary
recommendations. Therefore, the outcomes of the three breakout
groups from the breakout sessions 1 and 2, respectively, are pre-
sented jointly, rounded up by comments provided during the
subsequent plenary discussions.4.1. Breakout session 1: the future role of ncRNAs in regulatory
toxicology
Breakout group 1. Moderator: Helmut Greim; rapporteur: Alan
Poole
Breakout group 2. Moderator: Tim Gant; rapporteur: Madeleine
Laffont
Breakout group 3. Moderator: Roland Buesen; rapporteur:
Achim Aigner
Generally, there are three important drivers of research on
ncRNAs as biomarkers for regulatory toxicology. First, the 3Rs
principle to reduce the number of studies and the number of ani-
mals used in the studies (Russell and Burch, 1959) that has been
implemented in Directive 2010/63/EU on the protection of animals
used for scientiﬁc purposes. Second, the motivation to streamline
and accelerate substance development and the RA process.
(Research on ncRNAs might also serve to use the respective tech-
nologies to modify, e.g., plants and therapeutic agents.) Third, the
incentive to gain knowledge that is of increased biological and
toxicological relevance.
Accordingly, research on ncRNAs as biomarkers for regulatory
toxicology should not only strive to replace apical endpoints by
earlier molecular or cellular effects, but it should aim to create a
new toxicological paradigm that provides more comprehensive
information. In certain areas of toxicology, the current standard
tests have scientiﬁc shortages. Knowledge gaps include, but are not
restricted to ways to assess non-genotoxic carcinogenicity and
reproductive/transgenerational toxicity, including in utero expo-
sure leading to adult diseases, the effects of long-term low-dose
exposure and problems in the toxicological evaluation of mixtures.
Research to enhance the utility of ncRNAs as biomarkers for regu-
latory toxicology should also address such scientiﬁc shortages of
standard toxicity tests and the way that speciﬁc ncRNAs might
contribute to overcoming them. Even though the goal to gain
knowledge that is of increased biological and toxicological rele-
vance might only be reached in the long term, it is of high scientiﬁc
relevance since an improved biological understanding of mecha-
nisms of toxicity will serve to improve the RA of substances and
products.
Current research is most advanced for miRNAs. Nevertheless, for
the time being, ncRNA-related research aiming at identifying bio-
markers for regulatory toxicology should not be restricted to
promising miRNAs, but it should also be open to possibly emerging
evidence on the suitability of other classes of ncRNAs, such as
lncRNAs.
All research questions should be pursued in literature reviews
and in experimental projects. To gain new data, it might be bene-
ﬁcial to include ncRNA expression proﬁling, just as ‘omics and
epigenetics technologies, in the control groups of Good Laboratory
Practice-compliant rat 90-day oral toxicity studies that include
properly deﬁned kinetics and (histo-)pathological evaluations.
Thereby, ncRNA assessments will be performed in parallel with
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up. All research should preferably be conducted in the form of
collaborative studies, pooling data from different companies and
institutions. All of these premises will allow collecting ncRNA data
within a regulatory context, and they will enhance a prospective
comparative assessment of the new tools.
To determine the role that ncRNAs might play in regulatory
toxicology, a proﬁle of the ‘normal’ situation and its variations in
maintaining cellular homeostasis remain to be elucidated. The
historical control databases will provide an overview of the ranges
of normal ncRNA expression levels. Further, the dose-response re-
lationships of substance-induced deviations from normality and
the phenotypic consequences of different ncRNA expression levels
should be determined. These actions will serve to identify key
ncRNAs that are relevant for cell homeostasis or pathogenesis, as
applicable.
Beyond an assessment of differences in ncRNA expression pro-
ﬁles that will be relevant for toxicological assessments (physio-
logical variations vs. pathological changes), optimal testing systems
have to be deﬁned with regard to pathological readout and kinetics
over time. An understanding on mechanisms of toxicity involving
ncRNAs will form a basis to determine species-speciﬁc and tissue-
speciﬁc differences in susceptibility to substance-induced effects. It
will be of great value for RA to identify ncRNAs that are related to
the development of speciﬁc apical effects and to be able to trace
them in vitro and in vivo and across animal species and strains.
Research addressing the possible relevance of changes in the
expression of selected ncRNAs for toxicological assessments should
strive to distinguish between physiological variations and patho-
physiological alterations. To date, it is unclear which order of
magnitude is relevant for a given ncRNA, i.e. which changes can
lead to downstream effects on established target genes. Further,
speciﬁc MoAs have not yet been discerned. Ideally, all knowledge
gained on pathophysiological alterations of ncRNA expression
should be integrated into AOPs, e.g. by identifying the speciﬁc
consequences of ncRNA alterations on different levels, including
protein levels, enzyme compositions, and deviations from the
phenotype.
Relevant body compartments for ncRNA analysis need to be
deﬁned. This includes non-invasive (blood, urine, and other body
ﬂuids) and invasive assessments (classical additional target organs
depending on prior non-invasive analysis to identify representative
miRNAs for speciﬁc organs or for speciﬁc early events, e.g. with
respect to tumour development). As the example of miRNAs that
are involved in acetaminophen hepatotoxicity reveals, substance-
induced miRNA changes can be investigated in a time-dependent
manner already shortly after exposure to the substance when
conventional parameters are not yet affected (Ward et al., 2012). In
fact, this constitutes one of the advantages of ncRNA expression
proﬁling over conventional techniques. Also with respect to
substance-induced carcinogenicity, different ncRNA expression
proﬁles are to be expected during pre-tumour and post-tumour
investigations. Hence, changes in ncRNA expression should al-
ways be investigated in a time-dependent manner, and they should
always be related to normal expression levels.
All research efforts should be application-oriented. The stan-
dardization and validation of ncRNA expression proﬁling technol-
ogies should be advanced, and guidelines on the reporting of data
and results from ncRNA studies should be set up. NcRNA-related
tools will most likely not be beneﬁcial in isolation, but they will
add to a weight-of-evidence during RA. Accordingly, ncRNA
expression proﬁling should be considered together with other
modern technologies, such as ‘omics and epigenetics.
Finally, ncRNA-related research should not be restricted to
carcinogenicity-related topics, but it should cover a wide range oftoxicological endpoints. The pathological consequences and
respective changes in ncRNA expression of long-term low-dose
substance applications should also be addressed.
4.2. Breakout session 2: research priorities and focus areas for
industry and other funders
Breakout group 1. Moderator: Alan Poole; rapporteur: Nigel
Gooderham
Breakout group 2. Moderator: Reza J. Rasoulpour; rapporteur:
Saskia van der Vies
Breakout group 3. Moderator: J€org Hackermüller; rapporteur:
Madeleine Laffont4.2.1. Literature survey
Comprehensive literature surveys should be conducted to re-
view the state-of-the-art role that ncRNAs play in the evolvement
of apical effects. Such surveys should aim to identify key ncRNAs
that might be predictive biomarkers for speciﬁc toxicological end-
points. At least initially, well-established ncRNAs should be
addressed with priority, which will most likely mainly include
miRNAs (e.g. miR-155 and miR-122). Nevertheless, the survey
should also take into account other classes of ncRNA (e.g., the
lncRNA HOTAIR). Additionally, promising candidates may be ob-
tained by bioinformatic re-analysis of existing data sets. The suit-
ability of candidate ncRNA should be deﬁned with regard to organ
and tissue speciﬁcity and pathological functionality (e.g. tumour
promoting properties). The review should cover all available rele-
vant information on ncRNAs. In this regard, ‘relevant’ studies
should cover both ncRNA expression analysis and phenotype
assessments.
As an outcome of the literature survey, a list of candidate
ncRNAs to choose from for the subsequent experimental project
should be drawn up. This list may also include new, hitherto un-
tested ncRNAs.
4.2.2. Experimental project
To substantiate the relevance of selected ncRNAs as biomarkers
for toxicity studies, retrospective analyses of ncRNA expression
proﬁles (e.g. from surplus samples from control groups from
existing regulatory studies) may be supplemented by performing
new 90-day rat oral toxicity tests. The experimental project should
be designed to allow the determination of dose-response re-
lationships, and it should include ncRNA proﬁling of blood samples.
The choice of rat strain should be justiﬁed, just as the selection of
2e3 target organs (e.g. liver, thyroid, and kidney). All studies should
be run in parallel in multiple laboratories, and blinded samples
should be used for ncRNA analysis.
The experimental project should aim at establishing normal (i.e.
physiological) ncRNA expression proﬁles that include the biological
variability of healthy individuals (i.e. the control groups). Covering
the range of intra- and inter-individual variability in ncRNA
expression levels, the biological variability is most likely affected by
a multitude of parameters, including polymorphic differences and
the diet.
The normal ncRNA expression proﬁles should be used to assist
in the interpretation of substance-induced changes in ncRNA
expression proﬁles. It should be strived to link proﬁles to patho-
logical ﬁndings (phenotypic alterations). This should also serve to
improve an understanding of MoAs. Therefore, the experimental
project may be speciﬁcally designed to address areas of toxicology
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genotoxic carcinogenesis, immunotoxicity, reproductive/intergen-
erational toxicity, or low-dose and long-term toxicity).
The experimental project may also be conducted in the form of
case studies investigating, e.g., changes in the expression of speciﬁc
ncRNAs taking into account dose-response relationships and tem-
poral aspects. Such case studies should address whether the poly-
morphism of ncRNAs is likely to have functional consequences and
whether speciﬁc epigenetic events govern other epigenetic events.
Generally, the project should consider the results from relevant
disease-related genomics projects, and data-sharing between
different companies and public health departments should be
encouraged. As an outcome of this project, new predictive bio-
markers of toxicity and disease states should be identiﬁed. For
instance, it might be shown that a hepatotoxic substance does not
change the ncRNA proﬁle in other organ systems.
Subsequent follow-up research should include a veriﬁcation and
validation of the ncRNA expression proﬁling, e.g., by using unspe-
ciﬁc chemicals and/or by including further organ systems in the
follow-up studies. Additionally, data fusion approaches should be
used to comparatively analyse ncRNA expression proﬁles, data from
‘omics and epigenetics technologies, and ﬁndings gained using
classical toxicological parameters (including (histo-) pathological
evaluation). This will provide added value from existing informa-
tion and advance a meaningful and comprehensive interpretation
of data obtained in ncRNA expression proﬁling, ‘omics and epige-
netics technologies. Even though the precise relationships between
these data (or technologies) are not yet understood, they all merge
into speciﬁc AOPs.
Consensus should be developed on how to conduct ncRNA
expression proﬁling in a toxicological and regulatory context,
including best practice of reporting the outcome of such studies.
This part of the experimental work should also encompass initia-
tives to improve the standardization of the respective technologies
to form a basis for their veriﬁcation and validation and to set up
guidelines for reporting the outcome of ncRNA studies.
5. Close of the workshop
Wrapping up the workshop, Helmut Greim, Technical University
Munich, Germany, highlighted that, in the long-term, knowledge of
ncRNAs can serve to understand speciﬁc mechanisms of toxicity,
e.g., with respect to genotoxic and non-genotoxic carcinogenicity,
reproductive/transgenerational toxicity, mixture toxicology, and
long-term low-dose effects. All ncRNA methodologies should be
standardised and validated, and guidance for the reporting of data
should be established. NcRNA analysis tools can be incorporated
into standardised in vitro assays and in vivo repeated-dose studies
used for RA, applying a holistic approach that incorporates epige-
netic mechanisms, ‘omics technologies (and gene methylation and
acetylation) and that serve to establish correlations between
changes in ncRNA expression and the corresponding changes in
cellular function.
Taken together, the research priority areas identiﬁed during the
workshop will serve to recognize key ncRNAs that are relevant for
cell homeostasis and/or pathogenesis and to advance a mechanistic
understanding of toxicological pathways. The outcomes of the
projects should be used to integrate knowledge on ncRNAs into
AOPs, e.g. to identify the consequences of changes in the expression
of a given ncRNA on the subsequent steps of a relevant AOP,
including protein levels, enzyme compositions, and deviations
from the phenotype.
Importantly, all those involved in regulatory toxicology and the
RA of substances should be continuously informed on the potential
applicability of ncRNA data for RA. In the long term, ncRNAexpression proﬁling has the potential to improve RA by enhancing
hazard predictions at earlier stages, and it may serve the goals to
reduce animal testing and to reduce the costs and time required to
market innovative products.
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